Logo

James Angus McDonald, Tim Cowper

Jan 03, 2019

James Angus McDonald has left the board of directors of Oxford Nanopore Technologies as well as the board of its daughter companies, the Genome Foundry and Metrichor, effective Dec. 13, 2018. He had been a director for Oxford Nanopore since 2010, for Metrichor since 2013, and for the Genome Foundry since 2015. McDonald was immediately replaced as director of all three companies by Tim Cowper, Oxford Nanopore's vice president of finance. Cowper joined the firm in 2012 and oversees its financial team and strategic supply chain operations. In addition, in November 2018, he was appointed as director of Oxford Nanopore Manufacturing, a new daughter company.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.